Monto A S
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor 48109, USA.
Am J Respir Crit Care Med. 1995 May;151(5):1653-7; discussion 1657-8. doi: 10.1164/ajrccm/151.5_Pt_1.1653.
The occurrence of respiratory viruses in persons with asthma and COPD must be viewed against the behavior of the viruses in persons without these conditions. There are multiple agents involved, and reinfections with the same virus are frequent. Infections and illnesses generally decrease in frequency with increasing age. Thus, it can be expected that infections among children, with or without asthma, will be more frequent than among adults in general. Evaluation of studies of viral activity in persons with asthma and COPD should differentiate between increased susceptibility and production of exacerbations. The latter may simply indicate the potential for greater severity, but not a higher frequency, of infections. Whatever viruses are circulating at a particular time can produce exacerbations; the studies are most conclusive for asthma in children, probably because infections in general are more common in this age group. Data also suggest increased susceptibility, although results are less clear than for exacerbations. Therefore, persons with chronic respiratory diseases should be considered a risk group for current and developmental vaccines and antiviral medications.
必须对照这些病毒在无哮喘和慢性阻塞性肺疾病(COPD)人群中的表现,来观察哮喘和COPD患者中呼吸道病毒的发生情况。涉及多种病原体,且同一病毒的再次感染很常见。感染和发病频率通常随年龄增长而降低。因此,可以预期,无论有无哮喘,儿童中的感染都将比一般成年人更频繁。对哮喘和COPD患者病毒活性研究的评估应区分易感性增加和病情加重的情况。后者可能仅表明感染的严重程度更高,但频率不一定更高。在特定时间传播的任何病毒都可能导致病情加重;这些研究对儿童哮喘最具说服力,可能是因为这个年龄组总体上感染更常见。数据也表明易感性增加,尽管结果不如病情加重那么明确。因此,慢性呼吸道疾病患者应被视为当前和正在研发的疫苗及抗病毒药物的风险人群。